Access
This article is part of Nature's premium content.
Published online 4 March 2002 | Nature | doi:10.1038/news020225-14
News
Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug
New candidate cancer drug does damage only in tumours.
A new drug turns lethal only when it reaches cancer cells. In healthy cells it is harmless.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
